Form 4: Beauty Health Co Director Michelle Kerrick Granted 73,051 Restricted Stock Units

Michelle C. Kerrick, a Director of The Beauty Health Company, was granted 73,051 Class A Common Stock shares in the form of Restricted Stock Units on June 16, 2025, increasing her direct beneficial ownership to 189,813 shares.

Summary

• Michelle C. Kerrick, a Director of The Beauty Health Company (SKIN), acquired 73,051 shares of Class A Common Stock.
• This acquisition occurred on June 16, 2025, and was reported via an SEC Form 4 filing on June 18, 2025.
• The shares were granted as Restricted Stock Units (RSUs), which are a form of equity compensation.
• Following this transaction, Ms. Kerrick's direct beneficial ownership of Class A Common Stock increased to 189,813 shares.
• The RSUs are set to vest on the earlier of the one-year anniversary of the grant date or the date of the Company's 2026 Annual Meeting of Stockholders, contingent upon her continued service as a board member.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, aligning interests and incentivizing long-term performance. It's a standard compensation practice, indicating stability rather than a significant positive or negative event.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with long-term shareholder value, as vesting is contingent on continued service and potential stock price appreciation.
• An increase in director ownership, even through grants, can signal confidence in the company's future prospects and commitment to its success.

Risks

• The vesting of the granted Restricted Stock Units is contingent upon Michelle C. Kerrick's continued service as a member of the Company's board of directors through the specified vesting date.

Future Outlook

The vesting schedule for the granted Restricted Stock Units indicates a future milestone tied to the one-year anniversary of the grant or the 2026 Annual Meeting of Stockholders, contingent on the director's continued service, aligning her long-term commitment with the company's performance.

Industry Context

This transaction is a standard form of equity compensation for directors in publicly traded companies, aiming to align their interests with long-term shareholder value. It reflects common corporate governance practices in the beauty and health industry, where attracting and retaining experienced board members is crucial for strategic oversight and growth.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common practice in corporate governance across various industries, including the beauty and health sector, to incentivize long-term commitment and align interests with shareholders.
• The specific number of units granted (73,051) would typically be evaluated against the company's overall compensation philosophy for non-employee directors and compared to similar grants at peer companies within the consumer discretionary or beauty industry, such as Estée Lauder Companies (EL), L'Oréal (OR.PA), or Ulta Beauty (ULTA), though specific comparable grants are not detailed in this filing.
• The vesting schedule, tied to continued service and a future annual meeting, is a standard mechanism to ensure retention and ongoing board engagement, consistent with best practices observed in companies like Procter & Gamble (PG) or Johnson & Johnson (JNJ) for their board compensation.

Corporate Governance

Related Party Transactions

• The grant of equity compensation to a director is considered a related party transaction, which is a standard and disclosed practice for public companies.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation. It also represents a form of dilution, though typically minor in the context of overall shares outstanding.
• Employees: No direct impact on employees is indicated by this director equity grant.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this director equity grant.

Next Steps

• Michelle C. Kerrick's continued service as a member of The Beauty Health Company's board of directors.
• Vesting of the Restricted Stock Units on the earlier of the one-year anniversary of the grant (June 16, 2026) or the date of the 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Beauty Health Co, SKIN, SEC Form 4, Restricted Stock Units, RSUs, Director Compensation, Insider Ownership, Equity Grant, Corporate Governance